Tyrosine Kinase Inhibitors (TKIS) and Imamune Checkpoint Inhibitors (ICIs) Were Recognized to Cause Endocrine Adversse Reactions (EARS). However, Combination Therapy-Associated Ears Are Still Unchlear.
This was Retrospective Study Based on FDA Adversse Event Reporting System. We identified 938,464 Cases of all adverse events related to Three Types of Treatments. The total of 22,275 cases were ears and divided into tkis (n = 9,181), icis (n = 11,363) and tkis+icis group (n = 1.731).
The Incidence of Ears was the Highest in Tkis+Icis FolloWed by Icis and Tkis Group. TKIS+ICIS GROUP HAD A HIGHER RISK OF HYPOTHYROIDISM THAN IN ICIS GROUP (OR 1.47, 95% CI (1.28-1.69)), WHILE A LOWER RISK COMPARED TO TKIS GROUP (OR 0.68, 95% CI (0.58-0.79)). TKIS+ICIS GROUP ABSED A HIGHER RISK OF TYPE 1 DIABETES MELLITUS COMPARED TO TKIS GROUP (OR 26.61, 95% CI (18.60-38.07)), But Lower Risk Compred to Icis Group (OR 0.63, 95% CI (0.47-0.84 ). The Risk of HypoglyCaemia wasproximately 2.77 Times Greater in Tkis+Icis Group Than in Icis Group (OR 2.77, 95% CI (1.95-3.95)) and was also Higher in Tkis Group to Icis Group (OR 3.4, 95% CI ( 2.93-4.03)). Compred to Icis Group, Tkis+Icis Group Did Not Display A Higher Risk of Pituitary Dysfunction and Primary Adrenal Insufficiecy. The Mortality Risk of Tkis+Icis Group was comparable to icis groups, but Significantly Lower Than Tkis Group.
Ears Were More Common in Tkis+Icis Therapy. The Distribution of Ears in Different Glands Varied Among Combination Therapy and Monotherapy. Combination Therapy-Associated Ears Did Not Increase the Risk of Mortality.
© The Author (s) 2025. Published by Oxford University Press on Behalf of the Endocrine Society. All Rights Reserved. For Commercial Re-Uuse, please contact [email protected] for reprints and Translation Rights for Reprints. All other permissions can be obtained throughout righttslink service via the permissions link on the article page on our website – first Further Information please contact [email protected]. See the Journal About Page for AddiTe Terms.
